Conversion Labs, Inc. (CVLB): Price and Financial Metrics

Conversion Labs, Inc. (CVLB): $29.40

0.09 (+0.31%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add CVLB to Watchlist
Sign Up

Industry: Medical - Drug Stores

Industry

NR

Ranked

#6 of 6

in industry

CVLB Price/Volume Stats

Current price $29.40 52-week high $33.02
Prev. close $29.31 52-week low $0.50
Day low $28.55 Volume 473,500
Day high $30.33 Avg. volume 1,046,458
50-day MA $13.85 Dividend yield N/A
200-day MA $7.21 Market Cap 681.52M

CVLB Stock Price Chart Interactive Chart >


Conversion Labs, Inc. (CVLB) Company Bio


Conversion Labs, Inc. operates as a direct response healthcare company that provides over the counter products and prescription medications to consumers worldwide. The company's products include Shapiro MD, a shampoo, conditioner, and leave-in-foamer for treating hair loss; iNR Wellness MD, a nutritional supplement for immune and gut support; RexMD for the treatment of cold sores, mental health, and various other medical conditions faced by men; SOSRx, a telemedicine brand that offers prescription medications and over-the-counter emergency preparation supplies for disaster situations, such as flu epidemics, bacterial outbreaks, bioterrorism and water supply failures, and others; and PDFSimpli, a PDF conversion software enables users to convert, edit, and sign PDF documents. It markets and sells its products through advertisements on Facebook, Google, Amazon, and other social media and e-commerce platforms. The company was formerly known as Immudyne, Inc. and changed its name to Conversion Labs, Inc. in June 2018. Conversion Labs, Inc. was founded in 1994 and is based in New York, New York.


CVLB Latest News Stream


Event/Time News Detail
Loading, please wait...

CVLB Latest Social Stream


Loading social stream, please wait...

View Full CVLB Social Stream

CVLB Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!